These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20004211)

  • 1. Evolution of resistance to anti-cancer therapy during general dosing schedules.
    Foo J; Michor F
    J Theor Biol; 2010 Mar; 263(2):179-88. PubMed ID: 20004211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.
    Foo J; Michor F
    PLoS Comput Biol; 2009 Nov; 5(11):e1000557. PubMed ID: 19893626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of acquired resistance to anti-cancer therapy.
    Foo J; Michor F
    J Theor Biol; 2014 Aug; 355():10-20. PubMed ID: 24681298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.
    Gallaher JA; Enriquez-Navas PM; Luddy KA; Gatenby RA; Anderson ARA
    Cancer Res; 2018 Apr; 78(8):2127-2139. PubMed ID: 29382708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosage strategies for delaying resistance emergence in heterogeneous tumors.
    Vakil V; Trappe W
    FEBS Open Bio; 2021 May; 11(5):1322-1331. PubMed ID: 33638275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating evolutionary dynamics into cancer therapy.
    Gatenby RA; Brown JS
    Nat Rev Clin Oncol; 2020 Nov; 17(11):675-686. PubMed ID: 32699310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of resistance to cancer therapy.
    Michor F; Nowak MA; Iwasa Y
    Curr Pharm Des; 2006; 12(3):261-71. PubMed ID: 16454743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Drug Interactions Determine Optimum Combination Strategies in Computational Models of Cancer Evolution.
    Chakrabarti S; Michor F
    Cancer Res; 2017 Jul; 77(14):3908-3921. PubMed ID: 28566331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of synergy and antagonism in designing multidrug adaptive chemotherapy schedules.
    Ma Y; Newton PK
    Phys Rev E; 2021 Mar; 103(3-1):032408. PubMed ID: 33862722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A theoretical quantitative model for evolution of cancer chemotherapy resistance.
    Silva AS; Gatenby RA
    Biol Direct; 2010 Apr; 5():25. PubMed ID: 20406443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients.
    Liu LL; Li F; Pao W; Michor F
    PLoS One; 2015; 10(11):e0141665. PubMed ID: 26536620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors.
    Lindsay D; Garvey CM; Mumenthaler SM; Foo J
    PLoS Comput Biol; 2016 Aug; 12(8):e1005077. PubMed ID: 27560187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance.
    Cassidy T; Nichol D; Robertson-Tessi M; Craig M; Anderson ARA
    PLoS Comput Biol; 2021 Aug; 17(8):e1009348. PubMed ID: 34460809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the role of phenotypic switching in cancer drug resistance.
    Gunnarsson EB; De S; Leder K; Foo J
    J Theor Biol; 2020 Apr; 490():110162. PubMed ID: 31953135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors.
    Dallavalle S; Dobričić V; Lazzarato L; Gazzano E; Machuqueiro M; Pajeva I; Tsakovska I; Zidar N; Fruttero R
    Drug Resist Updat; 2020 May; 50():100682. PubMed ID: 32087558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolutionary analysis of replicator dynamics about anti-cancer combination therapy.
    Zhao R; Lai X
    Math Biosci Eng; 2023 Jan; 20(1):656-682. PubMed ID: 36650783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation study.
    Axelrod DE; Vedula S; Obaniyi J
    Cancer Chemother Pharmacol; 2017 May; 79(5):889-898. PubMed ID: 28343282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Resistance on Therapeutic Design: A Moran Model of Cancer Growth.
    Lacy MS; Jenner AL
    Bull Math Biol; 2024 Mar; 86(4):43. PubMed ID: 38502371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical drug resistance: the role of factors other than P-glycoprotein.
    Kaye SB
    Am J Med; 1995 Dec; 99(6A):40S-44S. PubMed ID: 8585535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taking a break from chemotherapy to fight drug-resistance: The cases of cancer and HIV/AIDS.
    Hadjiandreou MM; Mitsis GD
    Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():197-200. PubMed ID: 24109658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.